Trial · NCT03223337
Outcomes30
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 30 of 30
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863 | Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose | Pharmacodynamic Population | Hours* International units per liter | MEAN |
| SECONDARY | Part 2: AUC (0-t, EPO) Following Administration of GSK1278863 | Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose | Pharmacodynamic Population | Hours* International units per liter | MEAN |
| SECONDARY | Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 16 days | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 2: Number of Participants With AEs and SAEs | Up to 16 days | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline | Baseline (Screening) and up to Day 16 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline | Baseline (Screening) and up to Day 16 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline | Baseline (Screening) and up to Day 16 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline | Baseline (Screening) and up to Day 16 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 1: Number of Participants With Abnormal Urinalysis Findings | Up to Day 16 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part 2: Number of Participants With Abnormal Urinalysis Findings | Up to Day 16 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03223337/outcomes?page=2